Acute-graft-versus-host Disease Clinical Trial
Official title:
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease
Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties. In a recent phase 2 study, CBD has been shown to be safe and reduced significantly the incidence of acute GVHD compared to control patients with a hazard ratio of 0.3. Based on these results the investigators propose a phase 2 study to explore the efficacy of oral CBD in the treatment of severe (grades III/IV) acute GVHD, a pathology with a dismal prognosis.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
| Completed |
NCT05121142 -
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02175615 -
Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT
|
||
| Recruiting |
NCT05078073 -
HBOT in the Treatment and Prevention of aGVHD
|
N/A | |
| Not yet recruiting |
NCT03605940 -
A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease
|
Phase 2 | |
| Completed |
NCT04014790 -
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT03148743 -
Fecal Microbiota Transplantation in Gut aGVHD Treated
|
||
| Recruiting |
NCT03805789 -
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04291261 -
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT05123040 -
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04686929 -
Abatacept s.c. for aGVHD Prevention in Haplo-HCT
|
Phase 1/Phase 2 | |
| Completed |
NCT03763318 -
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03764228 -
Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT03339297 -
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
|
Phase 2 | |
| Active, not recruiting |
NCT03847844 -
UCMSCs as Front-line Approach of Treatment for Patients With aGVHD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05149365 -
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation
|
Phase 3 | |
| Not yet recruiting |
NCT04883918 -
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|
Phase 2 | |
| Terminated |
NCT01220297 -
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
|
Phase 2 | |
| Recruiting |
NCT05263999 -
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
|
Phase 3 | |
| Recruiting |
NCT05352269 -
Safety and Tolerability of FMT Capsules in Healthy Volunteers
|
Phase 1 |